Health
NICE okays regular NHS funding for Novartis’ breast cancer drug Kisqali – – pharmaphorum
NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for previously treated breast cancer patients….
NICE has recommended moving Novartis Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients.
In the final draft guidance, NICE recommended Kiskali be taken out of the Cancer Drugs Fund, which has been providing interim reimbursement since 2019 until further trial data emerged addressing uncertainties about overall survival and cost-effectiveness.
These data are now available from the phase 3 MONALEESA-3, a randomised…
Continue Reading
